What is the role of degludec (Tresiba) in the treatment of type 1 diabetes mellitus (DM)?

Updated: Sep 13, 2019
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print
Answer

A new ultralong-acting basal insulin, insulin degludec (Tresiba), which has a duration of action beyond 42 hours, has also been approved by the FDA. It is indicated for diabetes mellitus types 1 and 2. A combination product of insulin degludec and the rapid-acting insulin aspart was also approved (Ryzodeg 70/30). Approval was based on results from the BEGIN trial [110, 111, 112] that showed noninferiority to comparator productions. The cardiovascular outcomes trial (DEVOTE) comparing cardiovascular safety of insulin degludec to that of insulin glargine in patients with type 2 DM is ongoing.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!